Supporting the feasibility of future exploration of Grm3 inhibition in glioma patients, a similar negative allosteric modulator of Grm2/3 (decoglurant) was well tolerated by patients treated in a phase II clinical trial of major depressive disorder (ClinicalTrials.gov: NCT01457677). Here, GRM3 is linked to central nervous system cancer.